세계의 착상 전 유전자 검사(PGT) 시장 : 성장 기회, 성장 촉진요인, 산업 동향 분석 및 예측(2024-2032년)

The Global Preimplantation Genetic Testing (PGT) Market, valued at USD 780.8 million in 2023, is projected to grow at a CAGR of 9.4% from 2024 to 2032. This growth is driven by a rising awareness of reproductive health and a growing demand for genetic disorder screening in newborns. PGT provides families with a proactive option to detect genetic abnormalities in embryos before implantation, helping prevent hereditary conditions and enhancing overall reproductive outcomes. The market is segmented by product and service categories. The product segment, which includes essential reagents, sequencing kits, and testing consumables used in IVF procedures, led the market in 2023 and is expected to grow at a CAGR of 9.3% during 2024-2032. The increasing rate of genetic disorders, coupled with the expanding adoption of IVF, has heightened the demand for these kits and consumables.

Recent advancements in genetic technologies like next-generation sequencing (NGS) have driven demand and created more precise and efficient testing kits. The consumables' recurring nature also ensures a stable revenue stream, underscoring the profitability of this segment. Technologically, the PGT market includes NGS, fluorescent in-situ hybridization (FISH), polymerase chain reaction (PCR), array-based methods, and more. NGS holds the largest market share at 42% in 2023 due to its speed, accuracy, and ability to detect a wide range of genetic abnormalities in one test.

This technology can sequence multiple embryos simultaneously, reducing costs and increasing efficiency for fertility clinics and researchers. As the demand for precise screening intensifies, the adoption of NGS in PGT continues to rise, establishing it as a leader in reproductive genetic technology. Regionally, the U.S. dominated the North American PGT market in 2023, accounting for USD 312.2 million, and is expected to maintain this lead through the forecast period. The country's extensive adoption of advanced reproductive technologies and a strong awareness of genetic screening contribute to this dominance.

Moreover, top fertility clinics and cutting-edge PGT providers further solidify the U.S. position in the North American market. The preimplantation genetic testing market is set for steady growth due to the increasing focus on reproductive health and genetic screening advancements. With product innovations and the expanding utilization of high-precision genetic technologies, the PGT market remains poised to meet the needs of a growing demographic seeking enhanced reproductive options.

Table of Contents

Chapter 1 Methodology & Scope

• 1.1 Market scope & definition
• 1.2 Research design
  • 1.2.1 Research approach
  • 1.2.2 Data collection methods
• 1.3 Base estimates & calculations
  • 1.3.1 Base year calculation
  • 1.3.2 Key trends for market estimation
• 1.4 Forecast model
• 1.5 Primary research and validation
  • 1.5.1 Primary sources
  • 1.5.2 Data mining sources

Chapter 2 Executive Summary

• 2.1 Industry 360° synopsis

Chapter 3 Industry Insights

• 3.1 Industry ecosystem analysis
• 3.2 Industry impact forces
  • 3.2.1 Growth drivers
    • 3.2.1.1 Rising incidence of genetic diseases
    • 3.2.1.2 Increasing prevalence of infertility rate
    • 3.2.1.3 Growing advancements in PGT technologies
  • 3.2.2 Industry pitfalls & challenges
    • 3.2.2.1 High cost of genetic testing
    • 3.2.2.2 Technical challenges in PGT methods
• 3.3 Growth potential analysis
• 3.4 Regulatory landscape
• 3.5 Technological landscape
• 3.6 Future market trends
• 3.7 Porter's analysis
• 3.8 PESTEL analysis

Chapter 4 Competitive Landscape, 2023

• 4.1 Introduction
• 4.2 Company market share analysis
• 4.3 Company matrix analysis
• 4.4 Competitive analysis of major market players
• 4.5 Competitive positioning matrix
• 4.6 Strategy dashboard

Chapter 5 Market Estimates and Forecast, By Product & Service, 2021 - 2032 ($ Mn)

• 5.1 Key trends
• 5.2 Products
• 5.3 Services

Chapter 6 Market Estimates and Forecast, By Technology, 2021 - 2032 ($ Mn)

• 6.1 Key trends
• 6.2 Next generation sequencing (NGS)
• 6.3 Polymerase chain reaction (PCR)
• 6.4 Fluorescent in-situ hybridization (FISH)
• 6.5 Array
• 6.6 Other technologies

Chapter 7 Market Estimates and Forecast, By Application, 2021 - 2032 ($ Mn)

• 7.1 Key trends
• 7.2 Aneuploidy screening
• 7.3 Structural chromosomal rearrangement
• 7.4 Monogenic/single-gene disorder screening
• 7.5 Human leukocyte antigen (HLA) typing
• 7.6 Other applications

Chapter 8 Market Estimates and Forecast, By End Use, 2021 - 2032 ($ Mn)

• 8.1 Key trends
• 8.2 Hospitals & clinics
• 8.3 Diagnostic laboratories
• 8.4 Fertility centers
• 8.5 Research institutes

Chapter 9 Market Estimates and Forecast, By Region, 2021 - 2032 ($ Mn)

• 9.1 Key trends
• 9.2 North America
  • 9.2.1 U.S.
  • 9.2.2 Canada
• 9.3 Europe
  • 9.3.1 Germany
  • 9.3.2 UK
  • 9.3.3 France
  • 9.3.4 Spain
  • 9.3.5 Italy
  • 9.3.6 Netherlands
• 9.4 Asia Pacific
  • 9.4.1 China
  • 9.4.2 Japan
  • 9.4.3 India
  • 9.4.4 Australia
  • 9.4.5 South Korea
• 9.5 Latin America
  • 9.5.1 Brazil
  • 9.5.2 Mexico
  • 9.5.3 Argentina
• 9.6 Middle East and Africa
  • 9.6.1 South Africa
  • 9.6.2 Saudi Arabia
  • 9.6.3 UAE

Chapter 10 Company Profiles

• 10.1 Agilent Technologies
• 10.2 Fulgent Genetics
• 10.3 Genea BIOMEDX
• 10.4 Illumina
• 10.5 Medicover Genetics
• 10.6 Natera
• 10.7 Revvity
• 10.8 RGI
• 10.9 Takara Bio
• 10.10 Thermo Fisher Scientific
• 10.11 Varinos
• 10.12 Virtus Health
• 10.13 Vitrolife Group (Igenomix)